Dr. Tolcher is a Board-certified Medical Oncologist from San Antonio, TX, U.S.A., with significant experience in performing early-stage clinical trials with small and large molecules. Dr. Tolcher was previously co-founder and a leading member of START (South Texas Accelerated Research Therapeutics), managing a network of global clinical trial centers across the U.S., Europe, and Asia. Currently, Dr. Tolcher is founder and CEO of NEXT Oncology, and Director of Clinical Research in San Antonio, TX, U.S.A, a clinical research organization dedicated to advance highly innovative cancer medicines to first-in-human clinical trials.

He is a graduate of the University of British Columbia in Vancouver, Canada and performed his residency in internal medicine at the University of Toronto and his fellowship in oncology at the University of British Columbia. He followed this with a research fellowship at the National Cancer Institute, Bethesda, Maryland. Dr. Tolcher was a Fogarty Fellow at the National Institute of Health and received the Murray Muirhead Award for humanitarian and academic excellence and the Goel Prize in Medicine for excellence in the Clinical Disciplines. He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; and a member of the American College of Physicians, and the American Society of Clinical Oncologists. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee. He is an Associate Editor of The Journal of New Anticancer Agents; and he is a scientific grant reviewer for the National Cancer Institute of Canada.